Inhibitors of glycogen synthase kinase 3

US6489344B1 · kind B1 · utility

Assignee

• Chiron Corporation · US

Inventors

• John M. Nuss · Danville, US
• Stephen Harrison · Benicia, US
• David B. Ring · Palo Alto, US
• Rustum Boyce · San Francisco, US
• Sean P. Brown · Craydon Court, US
• Dane Goff · Redwood City, US
• Kirk W. Johnson · Berkeley, US
• Keith B. Pfister · Emeryville, US
• Savithri Ramurthy · Walnut Creek, US
• Paul A. Renhowe · Danville, US
• Lynn Seely · San Mateo, US
• Sharadha Subramanian · San Ramon, US
• Allan S. Wagman · Belmont, US
• Xiaohui Zhou · Shijiazhuang, CN

Key dates

• Filing date: Jun 18, 1999
• Grant date: Dec 3, 2002
• Expiry date: Jun 18, 2019

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.